Tim counsels investors, lenders, and providers on various healthcare transactional, regulatory, and enforcement matters related to mergers, acquisitions, joint ventures, investments, operations, and corporate governance.
Tim’s practice focuses extensively on healthcare regulatory and enforcement matters and has assisted clients in numerous healthcare-related areas, such as fraud and abuse regulations, health information privacy and security, FDA and life sciences regulatory compliance and risk, and operational and governance integration. Tim has assisted a broad range of clients on transactional and regulatory matters, including healthcare providers, private equity and other capital investors, banking and financial services, drug and medical device manufacturers and distributors, healthcare technology firms, management services organizations, insurance plans, and healthcare ancillary services firms.
Tim routinely provides guidance on the following:
Prior to joining the firm, Tim worked as a healthcare consultant and advised hospitals and health systems in the development and operational integration of new hospitals, freestanding EDs, and post-acute venues. Tim also worked as a law clerk for the American Medical Association updating physician compliance guidelines to ensure consistency with applicable law.
Represented a CBD and hemp extract manufacturer regarding state and federal regulations on their products and assisted them in structuring marketing and sale of products in existing healthcare markets.
Represented a private equity management firm in providing regulatory diligence and structural guidance related to its purchase of a minority interest in a leading, multi-state cannabis platform.
Represented global investment banks on healthcare regulatory and fraud and abuse issues in connection with its lending, acquisition funding, and loan restructuring for health systems, group practices, healthcare IT companies, post-acute venues, and nursing homes.
Counseled healthcare and life sciences companies on formation, restructuring, and syndication of new platforms, joint ventures, and management services organizations.
Represented a global operations management and analytics company in its acquisition of a healthcare utilization review firm and an IT analytics firm.
Conducted internal investigations for health systems, post-acute venues, and physician practices in relation to compliance with privacy and healthcare regulatory policies, procedures, and other applicable regulations.
Provided guidance as outside healthcare regulatory counsel to a national veterinary practice platform.
Conducted internal compliance reviews and audits related to compliance with healthcare laws and regulations and crafted responses to civil and criminal investigations conducted by federal and state government agencies for health systems and pharmaceutical and device clients.
Advised pharmaceutical and medical device manufacturers on FDA matters including state pharmacy/distribution laws, product marketing, product recalls, and manufacturing requirements.
Represented several mobile health application developers as healthcare regulatory counsel in structuring mobile health applications in accordance with healthcare and FDA laws and regulations.
Represented client as outside healthcare regulatory counsel in a Lanham Act case involving false claims for drug products.
Represented a private equity management firm as healthcare regulatory counsel in connection with its successful acquisition of a leading behavioral health platform.
Provided guidance as outside healthcare regulatory counsel to a national telehealth platform.
Young Professionals Board, Lawyers' Committee for Better Housing, 2019
Editor-in-Chief, Health Care Law Monthly, January 2018 – present
Member, American Society for Pharmacy Law
Member, American Health Lawyers Association
Member, Chicago Bar Association
Member, Illinois Association of Healthcare Attorneys
Selected for inclusion in Best Lawyers: Ones to Watch, Health Care Law, 2021, 2022
McGuireWoods Advises Cronos Group on Strategic Investment in PharmaCann
August 30, 2021
85 McGuireWoods Attorneys Recognized as ‘Ones to Watch’ By Best Lawyers
August 26, 2020
Hardey, Loveland Analyze FDA Guidance on Multifunction Medical Devices
September 10, 2018